BR112023005043A2 - Vacina contra covid-19 à base de piv5 - Google Patents

Vacina contra covid-19 à base de piv5

Info

Publication number
BR112023005043A2
BR112023005043A2 BR112023005043A BR112023005043A BR112023005043A2 BR 112023005043 A2 BR112023005043 A2 BR 112023005043A2 BR 112023005043 A BR112023005043 A BR 112023005043A BR 112023005043 A BR112023005043 A BR 112023005043A BR 112023005043 A2 BR112023005043 A2 BR 112023005043A2
Authority
BR
Brazil
Prior art keywords
piv5
vaccine against
covid
against covid
effective
Prior art date
Application number
BR112023005043A
Other languages
English (en)
Inventor
He Biao
Original Assignee
Univ Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Georgia filed Critical Univ Georgia
Publication of BR112023005043A2 publication Critical patent/BR112023005043A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
    • C12N2760/18741—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

VACINA CONTRA COVID-19 À BASE DE PIV5. A presente invenção refere-se a construtos do vírus da parainfluenza tipo 5 (PIV5) que expressa a proteína spike (S) do envelope de SARS-CoV-2 para uso como vacinas contra COVID seguras, estáveis, eficazes e econômicas.
BR112023005043A 2020-09-21 2021-09-21 Vacina contra covid-19 à base de piv5 BR112023005043A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063080862P 2020-09-21 2020-09-21
US202163217361P 2021-07-01 2021-07-01
PCT/US2021/051196 WO2022061264A1 (en) 2020-09-21 2021-09-21 Piv5-based covid-19 vaccine

Publications (1)

Publication Number Publication Date
BR112023005043A2 true BR112023005043A2 (pt) 2023-04-18

Family

ID=80776394

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023005043A BR112023005043A2 (pt) 2020-09-21 2021-09-21 Vacina contra covid-19 à base de piv5

Country Status (7)

Country Link
EP (1) EP4213872A4 (pt)
JP (1) JP2023542922A (pt)
AU (1) AU2021342576A1 (pt)
BR (1) BR112023005043A2 (pt)
CA (1) CA3196157A1 (pt)
MX (1) MX2023003199A (pt)
WO (1) WO2022061264A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113005149A (zh) * 2021-03-26 2021-06-22 中国农业大学 一种表达冠状病毒受体结合域串联二聚体的重组副流感病毒5型载体
CN113073116B (zh) * 2021-04-02 2022-11-11 中国农业大学 一种表达新冠病毒Spike蛋白重组副流感病毒5型制备和应用
GB202209861D0 (en) * 2022-07-05 2022-08-17 Univ Court Univ St Andrews Viral vectors
US20240148857A1 (en) * 2022-11-04 2024-05-09 Blue Lake Biotechnology, Inc. Recombinant rsv vaccine: methods of making and using the same

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108130345A (zh) * 2012-01-24 2018-06-08 乔治亚大学研究基金公司 基于副流感病毒5的疫苗
US20230105376A1 (en) * 2021-09-20 2023-04-06 Cyanvac Llc Piv5-based coronavirus vaccines and methods of use thereof

Also Published As

Publication number Publication date
MX2023003199A (es) 2023-04-13
JP2023542922A (ja) 2023-10-12
EP4213872A4 (en) 2024-03-27
AU2021342576A1 (en) 2023-04-06
EP4213872A1 (en) 2023-07-26
WO2022061264A1 (en) 2022-03-24
CA3196157A1 (en) 2022-03-24

Similar Documents

Publication Publication Date Title
BR112023005043A2 (pt) Vacina contra covid-19 à base de piv5
BR112023000323A2 (pt) Vacina combinada contra sars-cov-2 e influenza
CL2018002825A1 (es) Vacuna contra vrs
CL2018002394A1 (es) Subunidades de vacunas de inmersión para peces que comprenden al menos un antígeno aislado de la proteína análoga a histona (hlp) y su uso contra bacterias como flavobacterium. (divisional solicitud 2015000771)
AR068507A1 (es) Construcciones vector fluorocarbonado-antigeno para el suministro de antigenos ifluenza
CO2021003931A2 (es) Dosis unitaria de vacuna contra el dengue y administración de esta
CL2017001961A1 (es) Vacuna bivalente contra el virus de gripe porcina
BR112022016992A2 (pt) Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2
PE20151588A1 (es) Vacuna contra el virus del dengue
CO2019000214A2 (es) Vacuna contra virus de bronquitis infecciosa
CL2007000526A1 (es) Antigeno vacunal quimerico contra el virus de la influenza aviar, ia, que contiene el segmento extracelular de la hemaglutinina de la envoltura del virus de ia y el segmento extracelular de la proteina cd154; y composicion que lo comprende.
CU24580B1 (es) Vectores atenuados de influenza para la prevención y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncológicas
CL2017003224A1 (es) Vacuna contra el virus de la fiebre aftosa (fmdv) de virus vaccinia ankara modificado (mva) recombinante
AR101814A1 (es) Partícula de tipo virus flavivirus
CO2022014152A2 (es) Vacuna contra el virus de la peste porcina africana
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
AR115069A1 (es) Virus vacuna quimérico sintético
AR103427A1 (es) Vacuna contra la fiebre aftosa
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
PE20170429A1 (es) Vacuna en vector recombinante de adenovirus aviar serotipo 9
BRPI0516542A (pt) composição de vacina eficaz na prevenção ou melhora de infecção pelo vìrus da influenza aviária; método para prevenir ou melhorar a eclosão de infecção pelo vìrus da influenza aviária
BR112022020298A2 (pt) Vacinas, adjuvantes e métodos para gerar uma resposta imune
BR112016012435A2 (pt) Vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
CL2020002876A1 (es) Vacuna contra la bronquitis infecciosa (divisional de la solicitud no. 201803420)
CL2023001816A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada